Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015

SOUTH SAN FRANCISCO, Aug. 27, 2015 (GLOBE NEWSWIRE) — Portola Pharmaceuticals (Nasdaq: PTLA) today announced that results of a preclinical study of andexanet alfa will be presented in a moderated poster session at the European Society of Cardiology (ESC) 2015...

Notch3 Biomarker Results and Updated Data From OncoMed’s Phase 1b/2 PINNACLE Clinical Trial Accepted for Presentation at the 16th World Conference on Lung Cancer

REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) — New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3, OMP-59R5) in small cell lung cancer (SCLC) will be presented by...